Database
Obesity and peptide drug database
Every compound we track, with its main trial result. Tap a column to sort; tap a name for the full profile.
| TirzepatideZepbound / Mounjaro · Eli Lilly | GIP/GLP-1 dual agonist | Injection, weekly | FDA approved | 22.5% | 72 | 6.2% | 8.8 |
| RetatrutideNo brand yet · Eli Lilly | GIP/GLP-1/glucagon triple agonist | Injection, weekly | Phase 3 complete | 28.3% | 80 | 11.3% | 6.6 |
| CagriSemaNo brand yet · Novo Nordisk | Amylin + GLP-1 combination | Injection, weekly | Under FDA review | 22.7% | 68 | 6.0% | 5.2 |
| Oral semaglutide 25 mg*Wegovy pill · Novo Nordisk | GLP-1 receptor agonist | Oral, daily | FDA approved | 16.6% | 64 | 6.9% | 4.6 |
| Semaglutide 2.4 mgWegovy · Novo Nordisk | GLP-1 receptor agonist | Injection, weekly | FDA approved | 16.9% | 68 | 7.0% | 4.5 |
| OrforglipronFoundayo · Eli Lilly | Non-peptide GLP-1 agonist | Oral, daily | FDA approved | 12.4% | 72 | 10.3% | 3.4 |
| Semaglutide 7.2 mgWegovy HD · Novo Nordisk | GLP-1 receptor agonist | Injection, weekly | FDA approved | 20.7% | 72 | n/r | – |
| Liraglutide 3.0 mgSaxenda · Novo Nordisk | GLP-1 receptor agonist | Injection, daily | FDA approved | 8.0% | 56 | 9.9% | – |
| MazdutideApproved in China · Innovent / Eli Lilly | GLP-1/glucagon dual agonist | Injection, weekly | Approved in China | 14.8% | 48 | n/r | – |
| SurvodutideNo brand yet · Boehringer Ingelheim / Zealand | GLP-1/glucagon dual agonist | Injection, weekly | Phase 3 complete | 16.6% | 76 | 24.5% | – |
| MariTideMaridebart cafraglutide · Amgen | GLP-1 agonist + GIP receptor blocker (antibody) | Injection, monthly | In Phase 3 | 20.0% | 52 | 11.0% | – |
| AmycretinNo brand yet · Novo Nordisk | Amylin/GLP-1 unimolecular agonist | Injection or oral, weekly | In Phase 3 | 22.0% | 36 | n/r | – |
| EloralintideNo brand yet · Eli Lilly | Amylin receptor agonist | Injection, weekly | In Phase 3 | 20.1% | 48 | n/r | – |
| PetrelintideNo brand yet · Zealand Pharma / Roche | Amylin receptor agonist | Injection, weekly | Phase 3 starting | 10.7% | 42 | 1.0% | – |
| VK2735No brand yet · Viking Therapeutics | GIP/GLP-1 dual agonist | Injection (oral in development), weekly | In Phase 3 | 14.7% | 13 | n/r | – |
Weight loss: top dose, efficacy estimand where reported. Trials differ in length and population; Phase 2 results are not comparable with Phase 3. n/r = not reported.
* Wegovy pill: small trial with dose reductions. OASIS 4 included 307 adults, only about 205 of them on the pill, against 1,961 in STEP 1 for the injection, so its side-effect rates are less reliable. In addition, 18.6% of participants who completed treatment ended on a lower dose than 25 mg, which probably kept some from stopping and lowered the reported 6.9% discontinuation rate. Its ranking against the injection should be treated as provisional.